Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implement
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... IRVINE, Calif. , Aug. 31, 2015 /PRNewswire/ ... business and government, where regulations are often strict ... environment is driving a demand for professionals who ... interpret these regulations across a product lifecycle and ... organization. The University of California, Irvine Extension ...
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 2011 Reportlinker.com announces that a new market research ... Global Injectable Drug Delivery Market (2010 - 2015) ... KEY TAKE AWAYS * To ... its various sub-segments with respect to types of systems, ...
... Reportlinker.com announces that a new market research report ... European Markets for Minimally Invasive Spinal Devices ... The European minimally invasive spinal implant ... Rapid growth of the MIS interbody and MIS ...
Cached Medicine Technology:Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 2Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 3Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011 2
(Date:9/1/2015)... ... 2015 , ... September is Baby Safety Month, and Lightning Labels ... keep little ones' safety top of mind at all times. , Sponsored by the ... to the JPMA's Baby Safety Zone website, this year's theme is A Room with ...
(Date:9/1/2015)... ... September 01, 2015 , ... The premier online medical ... become a leader in podiatric, surgical and wound care conferences . The ... top national speakers at the podium and across the table during hands-on surgical ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, ... release of ten hours of new premium on-demand video Evidence Based Practice ... Athletic Trainers certified before 2014 must complete 50 CEUs before December 31, 2015, ...
(Date:8/31/2015)... , ... September 01, 2015 , ... ... eliminate chronic back pain – once required a long, arduous recovery. However, today’s ... stay, less pain, less blood loss and minimal muscle damage. These advantages of ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly ... Power and Influence by Modern Luxury’s The Atlantan Magazine. , This award ... as Kathy King. Her idea and vision to bring to Atlanta a true ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... reliability, improves information flow, facilitates documentation and, compliance, and ... ... outcomes., ... release of an enhanced NaviCare(R) WatchChild(R),solution, following receipt of marketing ...
... Additional Large Transactions in the Pipeline, LIVINGSTON, ... Board: MMGP) announced today that its wholly-owned,subsidiary, Genotec ... generates its sales from the distribution of its ... strategic,partners, has quoted on several large transactions for ...
... systems-based approach that combines comprehensive gene expression profiling with ... researchers to an important genetic marker that can help ... risk and will require more aggressive treatment, a research ... reports in the April 15, 2008, issue of the ...
... Anti-Tumor Activity, DALLAS, April 17 ... results from preclinical studies,ongoing at the prestigious ... monoclonal antibody. The new data, presented by ... Biochemistry,demonstrate that Angiolix has unusually high accumulation ...
... Eisai Corporation of,North America today announces the immediate ... Corporate Communications. In this newly created,position, Mr. Laverty ... Eisai,s corporate communications strategies and activities in the,United ... than 22 years of global corporate,product, policy and ...
... 17 A few years back, the,standard business card had ... side of plain vanilla paper stock, sometimes with,two-color printing to ... on both,sides of a BC in four-color process with a ... for 500 cards. This is a fraction,of what it cost ...
Cached Medicine News:Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:MM2 Group Provides Additional Quotes for New Venture in China 2Health News:Genome analysis reveals new protein associated with breast cancer progression 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 3Health News:Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications 2Health News:Your Business Card is a Powerful Marketing Tool 2
The Equator Convective Warmer incorporates LEVEL 1's unique, patented, temperature control technology to ensure delivery of the desired therapy to the patient....
The QuickVue Advance® G. vaginalis test is an enzyme activity test for use in the detection of Gardnerella vaginalis Proline IminoPeptidase(PIP) activity in vaginal fluid specimens from women su...
The Micro-Temp® II safely and consistently delivers a therapeutic level of localized heat using a pump, connecting hose and localized temperature therapy pad....
The Osom® Bvblue Test detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with Bacterial Vaginosis including Gardnerella, Bacteroides, Prevote...
Medicine Products: